Mantle Cell Lymphoma Pipeline 2025: Groundbreaking Clinical Advancements by 20+ Global Leaders - DelveInsight | Featuring AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences

With Mantle Cell Lymphoma reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Mantle Cell Lymphoma pipeline comprises 20+ pharmaceutical and biotech companies actively developing 22+ therapeutic candidates targeting Mantle Cell Lymphoma. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Mantle Cell Lymphoma Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders, including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Mantle Cell Lymphoma Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Mantle Cell Lymphoma Drug Development @ https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Mantle Cell Lymphoma Pipeline Report

DelveInsight's Mantle Cell Lymphoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Mantle Cell Lymphoma treatment.
In May 2025, results from the phase 2 ECOG-ACRIN E1411 trial (NCT01415752), adding bortezomib (Velcade) to bendamustine and rituximab (Rituxan; BR) as induction therapy did not lead to improved 2-year progression-free survival (PFS) compared with BR alone in patients with mantle cell lymphoma (MCL). However, Brad S. Kahl, MD, noted that the strong 2-year PFS achieved with BR alone has established a solid foundation for future advancements in MCL treatment.
In May 2025, Brad Kahl, MD, a professor of medicine, co-chair of the SCC Protocol Review and Monitoring Committee, and director of the Lymphoma Program at Washington University School of Medicine in St. Louis, highlighted the persistent treatment challenges in mantle cell lymphoma (MCL) and stressed the importance of advancing therapeutic options for various patient populations.
In February 2025, ROR1-targeted antibody-drug conjugate (ADC) zilovertamab vedotin (MK-2140) demonstrated antitumor efficacy and a tolerable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma (MCL), based on findings from cohort A of the phase 2 waveLINE-006 trial (NCT05458297) presented at the 2024 ASH Annual Meeting.
Key Mantle Cell Lymphoma companies such as AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences, and others are evaluating new drugs for Mantle Cell Lymphoma to improve the treatment landscape.
Promising Mantle Cell Lymphoma pipeline therapies in various stages of development include Venetoclax, Ixazomib, LP-168, PEP07, and others.

Mantle Cell Lymphoma Overview:

Mantle cell lymphoma (MCL) is an uncommon form of B-cell non-Hodgkin lymphoma (NHL), primarily defined by a chromosomal translocation between chromosomes 11 and 14. This rearrangement results in the overproduction of cyclin D1 (CCND1), a protein that drives tumor growth through disruptions in cell cycle regulation, genetic stability, and epigenetic control.

Though some MCL cases are straightforward to identify, diagnostic complexity arises due to diverse cellular appearances. Many patients are asymptomatic in early stages, but may later present with painless lymph node swelling, particularly in the neck and throat area (e.g., Waldeyer's ring).

Download the Mantle Cell Lymphoma sample report to know in detail about the Mantle Cell Lymphoma treatment market @ https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Mantle Cell Lymphoma Pipeline Analysis
The Mantle Cell Lymphoma pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Mantle Cell Lymphoma Market.

Categorizes Mantle Cell Lymphoma therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Mantle Cell Lymphoma drugs under development based on:

Stage of development

Mantle Cell Lymphoma Route of administration

Target receptor

Monotherapy vs. combination therapy

Mantle Cell Lymphoma Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Mantle Cell Lymphoma Licensing agreements

Funding and investment activities supporting future Mantle Cell Lymphoma market advancement.

Unlock key insights into emerging Mantle Cell Lymphoma therapies and market strategies here: https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Mantle Cell Lymphoma Emerging Drugs

Venetoclax: AbbVie

Venetoclax, marketed as VENCLYXTO, is a pioneering therapy that precisely targets the B-cell lymphoma-2 (BCL-2) protein, which plays a critical role in preventing programmed cell death (apoptosis) in certain blood cancers. By inhibiting BCL-2, venetoclax reactivates the cell's natural self-destruction mechanism, helping eliminate cancer cells.

Ixazomib: Takeda

Ixazomib is part of a class known as proteasome inhibitors, which act by blocking proteasomes-cellular machinery responsible for degrading unnecessary or damaged proteins. This inhibition interferes with essential cancer cell functions, suppressing their growth and survival.

Mantle Cell Lymphoma Pipeline Therapeutic Assessment

Mantle Cell Lymphoma Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Mantle Cell Lymphoma By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Mantle Cell Lymphoma Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Mantle Cell Lymphoma Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Mantle Cell Lymphoma therapies and key Mantle Cell Lymphoma companies: https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Mantle Cell Lymphoma Current Treatment Patterns
4. Mantle Cell Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Mantle Cell Lymphoma Late-Stage Products (Phase-III)
7. Mantle Cell Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Mantle Cell Lymphoma Discontinued Products
13. Mantle Cell Lymphoma Product Profiles
14. Mantle Cell Lymphoma Key Companies
15. Mantle Cell Lymphoma Key Products
16. Dormant and Discontinued Products
17. Mantle Cell Lymphoma Unmet Needs
18. Mantle Cell Lymphoma Future Perspectives
19. Mantle Cell Lymphoma Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Mantle Cell Lymphoma pipeline reports offerings: https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.